Company
Headquarters: George Town, Cayman Islands
CEO: Dr. Yun Yen F.A.C.P., FACP, M.D., Ph.D.
TW$10.88 Billion
TWD as of July 1, 2024
US$334.0 Million
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $622.07 B |
| Vertex Pharmaceuticals Incorporated | $121.36 B |
| Regeneron Pharmaceuticals, Inc. | $115.11 B |
| CSL Limited | $95.75 B |
| Marinomed Biotech AG | $75.67 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $808.65 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $450.89 B |
| Johnson & Johnson | $350.63 B |
| Merck | $318.75 B |
Tanvex BioPharma, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and sale of biosimilar and biologic products and drugs in Taiwan and the United States. The company's lead product candidate includes TX01 for the treatment of neutropenia. It also develops TX05, which has completed phase III clinical trial for the treatment of breast cancer; TX04 for the treatment of neutropenia; TX16 that has completed phase I clinical trial for the treatment of metastatic colorectal cancer; TX52, which is in pre-clinical trial; and other products. The company was formerly known as Ruenvex Biotech, Inc. Tanvex BioPharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Tanvex BioPharma, Inc. has the following listings and related stock indices.
Stock: TWSE: 6541 wb_incandescent